

Biotechnology Fund
SCHEDULE OF INVESTMENTS (Unaudited)

June 30, 2023

	Shares	Value
COMMON STOCKS[†] - 99.6%		
Biotechnology - 74.8%		
Amgen, Inc.	29,499	\$ 6,549,368
Vertex Pharmaceuticals, Inc.*	16,666	5,864,932
Gilead Sciences, Inc.	75,975	5,855,393
Regeneron Pharmaceuticals, Inc.*	7,199	5,172,770
Corteva, Inc.	66,663	3,819,790
Moderna, Inc.*	31,051	3,772,697
Biogen, Inc.*	13,120	3,737,232
Seagen, Inc.*	16,188	3,115,543
Illumina, Inc.*	16,606	3,113,459
Horizon Therapeutics plc*	28,592	2,940,687
Alnylam Pharmaceuticals, Inc.*	14,947	2,839,033
BioMarin Pharmaceutical, Inc.*	26,921	2,333,512
Royalty Pharma plc — Class A	73,910	2,271,993
Incyte Corp.*	33,033	2,056,304
United Therapeutics Corp.*	8,560	1,889,620
Sarepta Therapeutics, Inc.*	15,938	1,825,220
Apellis Pharmaceuticals, Inc.*	20,032	1,824,915
BioNTech SE ADR [†]	14,099	1,521,705
Exelixis, Inc.*	76,691	1,465,565
Ionis Pharmaceuticals, Inc.*	34,525	1,416,561
IVERIC bio, Inc.*	35,862	1,410,811
Halozyme Therapeutics, Inc.*	37,128	1,339,207
Argenx SE ADR [†]	3,355	1,307,544
CRISPR Therapeutics AG ^{†,1}	23,220	1,303,571
Guardant Health, Inc.*	35,051	1,254,826
Arrowhead Pharmaceuticals, Inc.*	32,138	1,146,041
Amicus Therapeutics, Inc.*	89,393	1,122,776
Karuna Therapeutics, Inc.*	4,871	1,056,276
Insmed, Inc.*	49,711	1,048,902
TG Therapeutics, Inc.*	41,688	1,035,530
Denali Therapeutics, Inc.*	34,728	1,024,823
Intellia Therapeutics, Inc.*	24,796	1,011,181
ACADIA Pharmaceuticals, Inc.*	41,581	995,865
Cytokinetics, Inc.*	29,571	964,606
Vir Biotechnology, Inc.*	37,940	930,668
Blueprint Medicines Corp.*	14,374	908,437
Prothena Corporation plc*	13,156	898,292
PTC Therapeutics, Inc.*	21,214	862,773
Ultragenyx Pharmaceutical, Inc.*	16,857	777,614
Mirati Therapeutics, Inc.*	20,808	751,793
Twist Bioscience Corp.* ¹	33,988	695,395
Beam Therapeutics, Inc.*	20,773	663,282
BioCryst Pharmaceuticals, Inc.*	87,758	617,816
Novavax, Inc.* ¹	65,159	484,131
Total Biotechnology		86,998,459
Pharmaceuticals - 19.2%		
AbbVie, Inc.	68,179	9,185,757
AstraZeneca plc ADR	43,539	3,116,086
Viatis, Inc.	213,872	2,134,442
Neurocrine Biosciences, Inc.*	19,244	1,814,709
Jazz Pharmaceuticals plc*	13,574	1,682,769
Alkermes plc*	48,792	1,527,190
Vaxcyte, Inc.*	20,773	1,037,404
Catalyst Pharmaceuticals, Inc.*	54,987	739,025
Ironwood Pharmaceuticals, Inc. — Class A*	64,765	689,099
Madrigal Pharmaceuticals, Inc.*	1,910	441,210
Total Pharmaceuticals		22,367,691
Healthcare-Products - 3.3%		
Exact Sciences Corp.*	26,336	2,472,950
Natera, Inc.*	27,947	1,359,901
Total Healthcare-Products		3,832,851
Healthcare-Services - 2.3%		
Medpace Holdings, Inc.*	5,659	1,359,122
Syneos Health, Inc.*	29,798	1,255,688
Total Healthcare-Services		2,614,810
Total Common Stocks		115,813,811
(Cost \$59,101,821)		
	Face Amount	
REPURCHASE AGREEMENTS^{††,2} - 0.6%		
J.P. Morgan Securities LLC issued 06/30/23 at 5.05% due 07/03/23	\$ 403,817	403,817
Barclays Capital, Inc. issued 06/30/23 at 5.06% due 07/03/23	177,659	177,659
BofA Securities, Inc. issued 06/30/23 at 5.06% due 07/03/23	161,508	161,508
Total Repurchase Agreements		742,984
(Cost \$742,984)		
	Shares	
SECURITIES LENDING COLLATERAL^{†,3} - 1.3%		
Money Market Fund		
First American Government Obligations Fund - Class X, 5.01% ⁴	1,568,762	1,568,762
Total Securities Lending Collateral		1,568,762
(Cost \$1,568,762)		
Total Investments - 101.5%		\$ 118,125,557
(Cost \$61,413,567)		
Other Assets & Liabilities, net - (1.5)%		(1,733,515)
Total Net Assets - 100.0%		\$ 116,392,042

* Non-income producing security.

† Value determined based on Level 1 inputs.

†† Value determined based on Level 2 inputs.

¹ All or a portion of this security is on loan at June 30, 2023.

² Repurchase Agreements.

³ Securities lending collateral.

⁴ Rate indicated is the 7-day yield as of June 30, 2023.

ADR — American Depositary Receipt

plc — Public Limited Company